Abstract
To investigate and compare the effects of troglitazone and rosiglitazone on plasma lipoproteins in patients with type 2 diabetes mellitus and dyslipidemia. This cohort study was conducted in the Diabetes Clinic of the University of Alabama. We identified and studied 18 patients with type 2 diabetes and dyslipidemia first treated with troglitazone (600 mg/day) and then transferred to rosiglitazone therapy (8 mg/day). By lowering insulin resistance, thiazolidinediones have common effects on lipoproteins; however, these drugs may have important differences in their effects on individual lipid particles. In our patients, both troglitazone and rosiglitazone increased low-density lipoprotein (LDL) levels; however, only rosiglitazone significantly changed the LDL particle size to the larger, less atherogenic LDL particle. Similarly, both troglitazone and rosiglitazone increased high-density lipoprotein (HDL) concentrations; however, although troglitazone increased only HDL(3), rosiglitazone also significantly increased the larger, more cardioprotective HDL(2) particle. Furthermore, only troglitazone increased Lp(a) significantly. In contrast, rosiglitazone and not troglitazone significantly increased triglycerides. Small but significa...Continue Reading
References
Dec 1, 1996·Diabetes·A R Saltiel, J M Olefsky
May 20, 1998·Diabetes Care·C J TackA F Stalenhoef
May 20, 1999·Diabetes Care·A E JärviB O Vessby
Feb 24, 2001·Annals of Internal Medicine·A A ParulkarV A Fonseca
May 26, 2001·The American Journal of Cardiology·P O Kwiterovich
Aug 11, 2001·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·D S BellS Shadmany
Citations
Mar 25, 2004·Clinical Therapeutics·Terry Meriden
Mar 29, 2008·Metabolic Syndrome and Related Disorders·David Bell
Jun 20, 2008·Diabetes, Obesity & Metabolism·D S H BellJ B McGill
Sep 29, 2011·Journal of Lipid Research·Aseel AlSalehThomas A B Sanders
Mar 4, 2005·Treatments in Endocrinology·David S H Bell
Sep 28, 2005·Treatments in Endocrinology·Emily Darby, Bradley D Anawalt
Dec 5, 2006·Atherosclerosis·Rajmund AdamiecAnna Sadakierska-Chudy
Nov 7, 2006·Atherosclerosis·Luciana BahiaEliete Bouskela
Jun 5, 2014·Pharmacogenomics·Paul PaoliniGary Hardiman
Oct 13, 2005·Diabetes, Obesity & Metabolism·Daniel E RosenbergBarry J Goldstein
Mar 2, 2012·Journal of Nutrigenetics and Nutrigenomics·Aseel AlsalehUNKNOWN RISCK Study investigators
Mar 29, 2008·Metabolic Syndrome and Related Disorders·Andrew J DrexlerLawrence H Young
Jul 15, 2003·Current Opinion in Cardiology·Daryl A CottrellJames M Falko
Aug 2, 2005·Treatments in Endocrinology·Alvin Huang, Philip Raskin
Oct 24, 2007·The Journal of Nutrition·Huiyun ShenBernhard Hennig
Nov 2, 2011·The Proceedings of the Nutrition Society·Aseel AlSalehSandra D O'Dell
Aug 18, 2004·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·David S H Bell
Sep 15, 2009·Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals·Xunde XianGeorge Liu
May 27, 2004·Diabetes Care·Ronald M Krauss